Article info
PDFReview
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
- Correspondence to Anne Sophie V M van den Heerik, Department of Radiation Oncology, Leiden Universitair Medisch Centrum, Leiden 2300 RC, The Netherlands; a.v.m.van_den_heerik{at}lumc.nl
Citation
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
Publication history
- Received July 1, 2020
- Revision received August 2, 2020
- Accepted August 4, 2020
- First published October 20, 2020.
Online issue publication
January 08, 2022
Article Versions
- Previous version (1 April 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.